Table 4.

Hormone replacement therapy in women with FFA.

First Author, Year	Type of Study	Studied Population	Hormone Replacement Therapy Use
Banka 2014 [49]	Retrospective study	N = 62 patients with FFA N1 = 1 male N2 = 61 females	N1 = 3 (5%) Hormone replacement therapy N2 = 4 (6%) Estrogen therapy (including one male patient, which does not constitute HRT) N3 = 2 (3%) Progesterone therapy
Panchaprateep 2020 [57]	Retro-prospective cohort study	N = 58 patients with FFA	N1 = 7 (12.1%) Received hormone replacement therapy
Imhof 2018 [50]	Retrospective study	N = 148 female FFA patients	N1 = 90 had hormone replacement therapy (HRT) (history documented in 90 patients) N2 = 57 (63.3%) history of HRT use in the form of systemic estrogen and/or systemic progesterone
Mervis 2019 [59]	Retrospective study	N = 91 patients with FFA N1 = 87 women N2 = 4 men N3 = 59.6 years mean age	N1 = 11 (13%) women either using hormonal birth control or HRT at the time of FFA diagnosis
Tosti 2005 [61]	Retrospective study	N = 14 women with FFA N1 = 62 years mean age (range 54 and 78 years)	N1 = 5 (35.7%) patients undergoing estrogen replacement therapy at debut
Kanti 2019 [36]	Observational, cross-sectional study	N = 490 FFA patients N1 = 467 (95%) female FFA patients N2 = 23 (5%) male patients with FFA N3 = 60 years mean age of onset of symptoms (IQR 53–68 years)	N1 = 22% had hormonal replacement therapy
Moreno-Arrones 2019 [14]	Case-control study	N1 = 578 women N2 = 289 women with FFA N3 = 289 female controls N4 = 77 men N5 = 19 men with FFA N6 = 58 male controls	N1 = 34 (11.8%) controls who used HRT N2 = 55 (19%) cases who used HRT p = 0.02
Suchonwanit 2020 [62]	Retrospective study	N = 56 patients with FFA N1 = 54 (96.4%) women with FFA N2 = 2 (3.6%) men with FFA N3 = 51 years–average age of disease onset (range, 39–80 years)	N1 = 7 (12.9%) received HRT
Meinhard 2014 [56]	Retrospective study	N1 = 31 women with FFA N2 = 1 man with FFA	N1 = 10 (32.3%) had HRT